Banamine® Transdermal, by Merck Group - Product details - Pubcompare (2024)

1

Flunixin Meglumine Administration in Piglets

Piglets were randomly allotted to one of three treatment groups differing by route of administration: intramuscular (IM, n = 7), oral (PO, n = 8), and transdermal (TD, n = 8). A randomized block design ensured that an even number of males and females were assigned to each group. After group allocation, a pre-trial blood collection was performed on each piglet. One mortality resulted due to jugular vein hematoma, and therefore the intramuscular group consisted of 7 piglets. Flunixin meglumine was administered at a target dose of 2.2 mg/kg for IM (Banamine®-S, Merck Animal Health, Madison, NJ, USA) administration and a target dose of 3.3 mg/kg for PO and TD (Banamine®-S and Banamine® Transdermal, Merck Animal Health, Madison, NJ, USA). Piglets were weighed the day prior to drug administration to calculate drug dose for each pig. A single-use needle and syringe was used to administer FM in the musculature of the lateral neck, behind the ear. A new feeding tube was used for orogastric intubation and PO administration of FM, followed by a volume of water equal to the volume of the tube to ensure administration of the full dose. TD application consisted of a single-use syringe to apply FM to the dorsal midline skin between the shoulder blades.

Kittrell H.C., Mochel J.P., Brown J.T., Forseth A.M., Hayman K.P., Rajewski S.M., Coetzee J.F., Schneider B.K., Ratliffe B., Skoland K.J, & Karriker L.A. (2020). Pharmacokinetics of Intravenous, Intramuscular, Oral, and Transdermal Administration of Flunixin Meglumine in Pre-wean Piglets. Frontiers in Veterinary Science, 7, 586.

2

Analgesic Treatments for Dehorning

A total of 61 calves were randomly assigned using a random number generator (Microsoft Excel, Microsoft Corporation, Redmond, WA, USA, 2018) to one of three treatment groups: 10 mL 2% lidocaine cornual nerve block only (L, n = 24), lidocaine nerve block +0.45 mg/lb (1 mg/kg) oral meloxicam (M, n = 20), or lidocaine nerve block +1.5 mg/lb (3.3 mg/kg) transdermal flunixin meglumine (F, n = 17) (Banamine Transdermal, Merck Animal Health; Madison, NJ, USA). Sample size differed for each treatment due to the order of randomization and the number of calves available during the study period. Sample size was calculated based on the ability to detect a predicted effect size for the salivary cortisol of 1 µg/dL with α = 0.10 and power = 0.85, which resulted in a sample size of at least 16 calves in each group.

Gaab T., Wright M, & Pierdon M. (2022). Behavioral and Physiological Response to Routine Thermal Disbudding in Dairy Calves Treated with Transdermal Flunixin Meglumine. Animals : an Open Access Journal from MDPI, 12(5), 533.

3

Florfenicol Pharmacokinetics in Steers

This study was approved by North Carolina State University’s Intuitional Animal Care and Use Committee. All methods and animal work were carried in accordance with animal welfare guidelines and with the ARRIVE guidelines. Twelve healthy 6–7month old steers (153.3–251.8kg) were enrolled in the study. The steer study size was based on previous gastrointestinal pharmacokinetic studies to demonstrate differences between the two dosing regimens^{8 (link),23 (link),24 (link)}. They were judged healthy by a physical exam on presentation and had no previous documentation of any antimicrobial administration. After a 3-day period of acclimation, the steers underwent gastrointestinal surgery for a different study^{8 (link)}. At the time of surgery, steers received either intravenous flunixin meglumine (2mg/kg, Banamine®, Merck Animal Health) or transdermal flunixin meglumine (3.3mg/kg, Banamine® Transdermal, Merck Animal Health).
Twenty-four to 48h after surgery, the steers were dosed with either 20mg/kg florfenicol (Nuflor®, Merck Animal Health) intramuscularly every 48h (n = 6) twice, or a single 40mg/kg subcutaneous dose (n = 6). The steers were randomly assigned via number generator to either of the treatment groups. The steers were housed in pairs (one from each treatment group) and fed grass hay with supplemental grain and free access to water for the duration of the study.

Halleran J., Sylvester H., Jacob M., Callahan B., Baynes R, & Foster D. (2024). Impact of florfenicol dosing regimen on the phenotypic and genotypic resistance of enteric bacteria in steers. Scientific Reports, 14, 4920.

4

Flunixin Pharmacokinetics in Donkeys

All donkeys received all treatments in the following order using a three-way crossover study design: oral (PO) by dosing syringe in oral cavity (BANAMINE^® (flunixin meglumine paste), IV via the jugular vein (Banamine^®-Injectable Solution, Merck Animal Health, Madison, NJ, USA), and TD along dorsal midline following the label instructions provided by the commercial BANAMINE^® TRANSDERMAL product [17 ]. A minimum two-week washout period was allowed between treatments. Oral and injectable (IV) flunixin was administered at a dose of 1.1 mg/kg of body weight to each donkey averaging 377 mg for PO. Transdermal was administered according to label instructions for cattle, 3.3 mg/kg BW (3 mL/100 pounds) dose for all donkeys. Donkeys received a single transdermal administration of 12 mL of flunixin. The product was applied along midline of the donkey’s back starting behind the withers and ending over the tail head without shaving coat hair. Throughout the course of each trial, all the donkeys were observed for any skin abnormalities and adverse behavioral effects.

McLean A.K., Falt T., Abdelfattah E.M., Middlebrooks B., Gretler S., Spier S., Turoff D., Navas Gonzalez F.J, & Knych H.K. (2023). Transdermal Flunixin Meglumine as a Pain Relief in Donkeys: A Pharmacokinetics Pilot Study. Metabolites, 13(7), 776.